218 related articles for article (PubMed ID: 19718055)
1. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.
Bacigalupo A; Soraru M; Dominietto A; Pozzi S; Geroldi S; Van Lint MT; Ibatici A; Raiola AM; Frassoni F; De Stefano F; Verdiani S; Casarino L; Barosi G
Bone Marrow Transplant; 2010 Mar; 45(3):458-63. PubMed ID: 19718055
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
[TBL] [Abstract][Full Text] [Related]
3. Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients.
Siragusa S; Passamonti F; Cervantes F; Tefferi A
Am J Hematol; 2009 Mar; 84(3):140-3. PubMed ID: 19123461
[TBL] [Abstract][Full Text] [Related]
4. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
6. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
7. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
[TBL] [Abstract][Full Text] [Related]
8. Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome.
Enright H; Daniels K; Arthur DC; Dusenbery KE; Kersey JH; Kim T; Miller WJ; Ramsay NK; Vercellotti GM; Weisdorf DJ; McGlave PB
Bone Marrow Transplant; 1996 Apr; 17(4):537-42. PubMed ID: 8722351
[TBL] [Abstract][Full Text] [Related]
9. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
[TBL] [Abstract][Full Text] [Related]
10. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Robin M; Tabrizi R; Mohty M; Furst S; Michallet M; Bay JO; Cahn JY; De Coninck E; Dhedin N; Bernard M; Rio B; Buzyn A; Huynh A; Bilger K; Bordigoni P; Contentin N; Porcher R; Socié G; Milpied N
Br J Haematol; 2011 Feb; 152(3):331-9. PubMed ID: 21133885
[TBL] [Abstract][Full Text] [Related]
12. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
15. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft.
di Grazia C; Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Berisso G; Bregante S; Dominietto A; Mordini N; Bruno B; Frassoni F; Bacigalupo A
Haematologica; 2001 Jun; 86(6):646-51. PubMed ID: 11418375
[TBL] [Abstract][Full Text] [Related]
16. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
Belkacémi Y; Labopin M; Hennequin C; Hoffstetter S; Mungai R; Wygoda M; Lundell M; Finke J; Aktinson C; Lorchel F; Durdux C; Basara N
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):544-51. PubMed ID: 17141976
[TBL] [Abstract][Full Text] [Related]
19. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose.
Sormani MP; Oneto R; Bruno B; Fiorone M; Lamparelli T; Gualandi F; Raiola AM; Dominietto A; Van Lint MT; Frassoni F; Bruzzi P; Bacigalupo A
Bone Marrow Transplant; 2003 Jul; 32(2):205-11. PubMed ID: 12838286
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.
Snyder DS; Palmer J; Stein AS; Pullarkat V; Sahebi F; Cohen S; Vora N; Gaal K; Nakamura R; Forman SJ
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1161-8. PubMed ID: 17085309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
